| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
7.26(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,579 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
91,318 |
237,059 |
410,079 |
888,401 |
| Total Sell Value |
$6,319,460 |
$16,812,843 |
$22,688,654 |
$44,103,545 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
4 |
16 |
36 |
82 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wysenski Nancy |
Director |
• • – |
2023-04-03 |
4 |
A |
$37.71 |
$5,619 |
D/D |
149 |
11,671 |
|
- |
|
| Henderson John T |
Director |
• • – |
2023-04-03 |
4 |
A |
$37.71 |
$19,986 |
D/D |
530 |
25,420 |
|
- |
|
| Wierenga Wendall D |
Director |
• • – |
2023-04-03 |
4 |
A |
$37.71 |
$11,238 |
D/D |
298 |
12,831 |
|
- |
|
| Kaye Edward M. Md |
Director |
• • – |
2023-04-03 |
4 |
A |
$37.71 |
$11,238 |
D/D |
298 |
13,347 |
|
- |
|
| Smith Sandford D |
Director |
• • – |
2023-04-03 |
4 |
A |
$37.71 |
$11,238 |
D/D |
298 |
12,831 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-28 |
4 |
AS |
$35.05 |
$438,125 |
D/D |
(12,500) |
441,058 |
|
-10% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-28 |
4 |
OE |
$9.65 |
$120,625 |
D/D |
12,500 |
453,558 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-15 |
4 |
AS |
$37.26 |
$465,750 |
D/D |
(12,500) |
441,058 |
|
-14% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-15 |
4 |
OE |
$9.65 |
$120,625 |
D/D |
12,500 |
453,558 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-03-09 |
4 |
AS |
$39.10 |
$156,400 |
D/D |
(4,000) |
171,183 |
|
-9% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
82,500 |
441,058 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
175,183 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-06 |
4 |
D |
$39.13 |
$465,647 |
D/D |
(11,900) |
358,558 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-06 |
4 |
AS |
$39.94 |
$499,250 |
D/D |
(12,500) |
370,458 |
|
-11% |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-06 |
4 |
OE |
$9.65 |
$120,625 |
D/D |
12,500 |
382,958 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
53,683 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• • – |
2023-03-06 |
4 |
D |
$39.13 |
$94,029 |
D/D |
(2,403) |
57,346 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
27,613 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
87,346 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-03-06 |
4 |
D |
$39.13 |
$194,007 |
D/D |
(4,958) |
135,183 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• • – |
2023-03-06 |
4 |
D |
$39.13 |
$27,078 |
D/D |
(692) |
21,613 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2023-03-02 |
4 |
D |
$39.60 |
$1,295,870 |
D/D |
(32,724) |
370,458 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• • – |
2023-03-02 |
4 |
D |
$39.60 |
$98,366 |
D/D |
(2,484) |
22,305 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• • – |
2023-03-02 |
4 |
D |
$39.60 |
$246,510 |
D/D |
(6,225) |
59,749 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• • – |
2023-03-02 |
4 |
D |
$39.60 |
$427,086 |
D/D |
(10,785) |
140,141 |
|
- |
|
1103 Records found
|
|
Page 6 of 45 |
|
|
0.91 (1.51%) 
